Objective: Some healthcare providers recommend hormone therapy (HT) cessation before mammography to improve performance. Our objective was to evaluate characteristics of women willing to consider HT cessation before screening mamography.
C urrently, some physicians encourage women to stop hormone therapy (HT) before receiving a mammogram in the hopes that short-term cessation will improve mammographic sensitivity and specificity, 1,2 but little is known about the characteristics of women who might be willing to consider short-term HT cessation. Women who use postmenopausal estrogen plus progesterone therapy (EPT) 3 for 4 or more years and women who have been using estrogen therapy (ET) for extended periods of time may be at increased risk for breast cancer. 4<6 In addition, postmenopausal HT has been shown to increase breast density, and increased breast density is a strong risk factor for breast cancer. 7<11 We performed a randomized clinical trial to test the hypothesis that HT cessation for 1 or 2 months before a screening mammogram would improve mammographic performance by decreasing breast density and mammography recall rates (recall for additional imaging). This report describes our recruitment experience and women's willingness to participate in the study. Our trial started recruitment after the publication of findings from the Women's Health Initiative (WHI) that EPT increases breast cancer risk. 5 We hypothesized that women who continued using HT in the wake of these findings, particularly women at higher risk for breast cancer, would be interested in, and willing to participate in, a study involving a short-term intervention designed to improve mammographic performance. We also hypothesized that women with more severe menopausal symptoms before starting HT might be less willing to participate, although our recruitment materials specifically stated that any woman who agreed to participate and was randomly assigned to HT cessation but became intolerant of symptoms during the study could immediately restart her HT.
METHODS

Study setting and eligibility
The Radiological Evaluation and Breast Density randomized clinical trial was conducted by Group Health, an integrated health plan in Washington State (United States) with approximately 550,000 members. Group Health has a population-based Breast Cancer Screening Program that women are invited to join when they turn 40 or when they join Group Health and are 40 years or older. 9 ,11<13 Demographic and breast cancer risk factor information is gathered via a self-administered questionnaire when women enter the Breast Cancer Screening Program and then at each subsequent screening mammogram. 9 We used automated administrative data to identify and recruit women aged 45 to 80 years who were due for a screening mammogram. To be eligible, women had to have had a screening mammogram (index) at Group Health within the past 2 years at which time they reported current HT use on a self-administered questionnaire. Women had to be due for a screening mammogram (study mammogram) and to have evidence of continued HT dispensing from Group Health pharmacies in the 6 months before study recruitment. We required that women self-report use of HT (denying use of HT was an exclusion criterion), and they were required to have at least two fills of a prescription for HT in the prior 6 months to be included in the study. Thus, we had evidence from two different sources regarding HT use. Estrogen dose was defined as follows: mediumV0.625 mg conjugated estrogens, 1 mg oral estradiol, 0.50 mg transdermal estradiol; lowVall doses less than the medium dose; and highVall doses greater than the medium dose.
Women were ineligible if they had a history of myocardial infarction, angina treated with medication, coronary revascularization surgery, stroke, blood clots, breast cancer, mastectomy or breast implants, or dementia or cognitive impairment. We further excluded women with any dispensing of tamoxifen or raloxifene from a Group Health pharmacy because of their potential influence on breast density. Women who had a breast density rating of Bentirely fat[ (Breast Imaging Reporting and Data System Center for Epidemiologic Studies Depression Scale density 1) on either breast at their index mammogram were also excluded because their density was not likely to influence mammography performance with or without HT.
This study was reviewed and approved by the institutional review boards at Group Health and the US Department of Defense.
Recruitment and refusal to participate
We recruited potentially eligible women during a 35-month period from November 2004 through September 2007, enrolling a median of 49 (range, 33-75) women per month. Women were initially contacted by mail with an introductory letter and study brochure. They were given the option to call a toll-free number if they did not want to be contacted further by the study team. We contacted potentially eligible women by telephone, invited them to participate, and further screened them for eligibility. We considered a participant enrolled after we verified her eligibility, she returned her consent form and Health Insurance Portability and Accountability Act authorization, and she was randomized to one of the study groups: (1) no, (2) 1-month, or (3) 2-month HT cessation.
During telephone screening, we asked women who refused participation to report the main reasons for refusal, which included the following: refused and were never randomized or if they consented and were randomized but then withdrew before any baseline data were obtained (with the exception of information on reasons for nonparticipation). We grouped these women into two categories: (1) those who refused participation because they were Bunwilling to stop HT[ and (2) those who refused participation for all Bother reasons.[ We only collected one primary reason for refusal for each woman. Because women may have had more than one reason for not wanting to participate, there is probably overlap between the refusal groups. The final percentage of eligible participants could not be determined because many women refused before their final eligibility was determined.
We modified recruitment materials 12 months into the study to emphasize to women that we welcomed their participation even if they were not sure they could maintain HT cessation, that they could restart their HT if their symptoms proved intolerable, and they could withdraw from the study for any reason, at any time.
Data collection
We used self-reported demographic characteristics, duration of HT use, and breast cancer risk information from the Group Health Breast Cancer Surveillance questionnaire 14 completed at the time of the index mammogram and before randomization. Years of enrollment and age were obtained from automated databases. Lifetime Gail model risk score was based on breast cancer risk factors collected at the index mammogram and was calculated using the National Cancer Institute's Breast Cancer Risk Assessment Tool. 15 Reasons for declining study participation were collected and maintained in the study recruitment records. Reasons for taking HT were recorded among study participants: Bto manage symptoms[ (including vasomotor symptoms, sleep disturbances, mood, vaginal bleeding, vaginal dryness, and sense of well-being), Bto prevent or treat osteoporosis,[ Bto prevent heart disease,[ Bdoctor told me to,[ and other.
Outcome
Factors associated with willingness to stop HT 1 to 2 months before a screening mammogram were evaluated, including age, race, ethnicity, years of education, hysterectomy, type and duration of HT use at the time of recruitment (ET vs EPT), body mass index (BMI), and breast cancer risk (lifetime Gail model risk score; first-degree relative with breast cancer). In addition, we evaluated differences in mammographic breast density (using Breast Imaging Reporting and Data System Center for Epidemiologic Studies Depression Scale categories) between participants and nonparticipants.
Analysis
We conducted two main comparisons to evaluate the characteristics of (1) all participants versus nonparticipants and (2) participants versus the two main groups of nonparticipants (refused to stop HT and refused for other reason). W 2 tests were used to compare differences between categorical variables, Wilcoxon rank sum, and Kruskal-Wallis tests for ordinal variables, and t tests and analysis of variance for continuous variables. We used multinomial logistic regression models to estimate the odds ratios for each of our two nonparticipant groups relative to participants (referent group).
Logistic regression models were also used to estimate the odds ratios for refusal for the combined nonparticipant group relative to participants, controlling for those factors that were associated with nonparticipation in the univariate analyses (P G 0.05). All analyses were run both with and without stratification by HT type (ET and EPT) in the 6 months before recruitment to the study. Finally, we assessed whether modifications to our recruitment materials influenced who was willing to participate.
RESULTS
Of the 5,861 women contacted to participate, 2,999 refused ( Fig. 1 ). An additional 169 women agreed to participate and were randomized but withdrew before data collection and are also considered nonparticipants for this analysis (total nonparticipation, 54.1%); 125 of the 169 were unwilling to stop HT. Unwillingness to stop HT was most often cited as the reason for nonparticipation (n = 1,876; 1,751 + 125) and accounted for 59.2% of 3,168 nonparticipants. Other common reasons for refusal were Bnot interested[ or Btoo busy[ (15.6%). Nearly one in three potentially eligible women invited to participate (n = 1,876; 32%) refused or withdrew before any participation because they were unwilling to stop HT use. Of those who enrolled in the study, 47% reported that they had tried to quit taking HT in the past, and approximately 75% used at least standard doses of estrogen. There were 247 women (16.1%) who did not list a specific symptom as a reason for HT use. Rather, they stated the reason for HT use as follows: Bto prevent or treat osteoporosis,[ Bto prevent heart disease,[ Bdoctor told me to,[ or other. There were 33 women (2.1%) who did not respond to the question about a reason for HT useVit is unknown whether this group of women was taking HT for symptoms.
There were few remarkable distinctions between women who agreed to participate and women who refused, although statistically significant differences were noted (Table 1) . Overall, the mean age was 61 years, most women were white (as compared to nonwhite, defined as Hispanic, black, Asian, American Indian/Alaska Native, or Native Hawaiian/Other Pacific Islander) with an average BMI of 27.3 kg/m 2 , most were taking ET (61%), and 52% had had a hysterectomy. Overall characteristics of participants were no different from those of nonparticipants with respect to Hispanic race, HT type (ET vs EPT), dose of ET, family history of breast cancer, and mammographic breast density. Women taking EPT were slightly less willing to discontinue HT use for 1 to 2 months before mammogram as compared with those women taking ET, but differences were not significant (31.5% EPT vs 33.4% ET; P = 0.18). All other factors did differ between the two groups, but the magnitudes of the differences were not clinically important. Overall, compared with participants, nonparticipants were older, had less education, and had lower BMI.
Univariate analyses evaluated the odds of refusal to participate by HT type and by reason for refusal ( Table 2) . Type of HT used (ET vs EPT) did not yield different findings, with a few minor exceptionsVthe CIs were wide; any apparent differences should be interpreted cautiously. Among ET users, older women, women with lower BMI, nonwhite women, or women with high school education or less were more likely to refuse participation, but the latter two findings were only true for women who refused participation for Bother reasons.[ Similarly, among women taking EPT, nonwhite women or women with high school education or less were more likely to refuse participation for Bother reasons.[ Women taking EPT had a greater likelihood of participation if they had a firstdegree relative with breast cancer as compared with those who did not.
After controlling for other factors, the odds of participation did vary by type of HT used (ET vs EPT) with respect to age, BMI, education, and first-degree relative with breast cancer, but not by race (Table 3 ). Among women taking ET, older women (Q71 y) or women with low BMI (G25 kg/m 2 ) had higher odds of being unwilling to participate as compared with younger women (e50 y) or women with higher BMI (Q25 kg/m 2 ), respectively. This association was not observed among women taking EPT. Conversely, among women taking EPT, those with a high school education or less had higher odds of refusal compared with women with a graduate school education, and women with a first-degree family history of breast cancer had lower odds of refusal compared with women without a family history of breast cancer. These associations were not observed among ET users. Again, the CIs for the estimated odds ratios in the stratified multivariable analysis overlapped, and differences by HT type should be interpreted cautiously.
Refining study materials to emphasize our interest in women who were willing to try to quit even if they had doubts about their ability to do so had no impact on who chose to participate (data not shown).
DISCUSSION
We conducted a randomized clinical trial among women due for a screening mammogram to test whether mammo-graphic performance could be improved with short-term HT cessation. One in three potentially eligible women who were invited to participate, knowing that this study might improve mammography performance, refused. Very few differences distinguished women who agreed to participate versus those who refused, emphasizing that among current HT users, overall resistance to HT cessation is strong, even when there may be an immediate personal benefit.
Breast cancer is one of the greatest fears for women considering HT use, 16, 17 and this same concern prompts many women to stop HT. 18 Thus, we presumed most women, particularly those taking EPT, would be willing to attempt HT cessation for 1 or 2 months on the premise that improved breast cancer screening might be achieved. We were surprised that 54% of women invited to join the study refused and that 59% of women who refused participation did so because of unwillingness to stop HT for 1 to 2 months, despite recruitment materials explaining that they could resume HT at any time during the study. Perhaps, unwillingness to stop HT could be explained by the fact that our study was performed 1 to 2 years after the major WHI publications describing the risks and benefits of HT. 6, 19 Our other studies have shown that the prevalence of HT use in our health plan (and other health plans) fell dramatically after the WHI publications, 3 suggesting that continued HT users are very committed and might be described as Bhard core users.[ Indeed, 47% of those who agreed to participate had attempted HT cessation in the past, and more than 84% acknowledged taking HT for symptoms.
We noted only minor differences in the characteristics of women who refused participation based on use of ET versus EPT, and arguably, any statistical differences between these groups were clinically insignificant. Women who refused participation had a lower BMI (predominantly ET) than those who agreed to participate. In addition, women who took EPT and agreed to participate had a higher risk of breast cancer (higher percentage of first-degree relatives) than those who refused participation, whereas this result was not observed among ET users. This finding might suggest that our participants have been educated regarding the WHI findings and understand that the WHI results showed an increased risk for breast cancer among EPT users and not among ET users. 5, 6, 19 Symptom severity is the most common reason that women report for inability to stop HT. 20 Although the women in our study were not asked specifically if refusal to participate was due to concern for return of severe menopausal symptoms, the work of others would suggest that indeed this is commonly the case. 20, 21 Observational studies show that among women who have been on HT for more than 1 year and try to quit, 25% resume HT within 6 months. 22 Ness and Aronow 21 reported that reasons for continued HT use included severe symptoms (34%), personal preference (10%), gynecologist recommended (9%), not documented (11%), and other (3%). Although these studies did not specifically address reasons associated with refusal to stop HT for short durations, they suggest that women continue HT use predominantly because of intolerable symptoms, despite known risks. Most likely, women who continued or started to use HT after the WHI findings have already made a personal decision that symptom benefits outweigh risks, and potentially, they view their personal risks as relatively low.
Others have shown that women who have had a hysterectomy are less likely to quit ET 20 as compared with women who have not had a hysterectomy and are using EPT. Contrary to these findings, we did not find that women taking EPT were more willing to discontinue HT use for 1 to 2 months before a mammogram as compared with those women taking ET (P = 0.18), although at baseline, more women overall were taking ET (62%) as compared with women taking EPT (38%). Interestingly, it is well recognized that the characteristics of women who take ET may vary from those of women who take EPT on multiple levels. Women who have had a hysterectomy are more likely to be nonwhite; have higher BMI; have lower education and income; have increased rates of hypertension, diabetes, hypercholesterolemia and depression; and be less physically active (all P G 0.01). 23, 24 Despite these differences, we did not find major differences between those women willing to participate based on estrogen dose or type of HT use (ET vs EPT).
Our study has several limitations. We did not collect data on symptom severity before starting HT because a number of women had been using HT for many years, so we could not fully assess symptom severity as a reason for nonparticipation. We also did not assess women's understanding regarding HT risks and benefits or to what degree they had made an informed decision whether to participate or not, based on their understanding of risks.
Despite several publications regarding the impact of HT discontinuation on breast density and possible mammographic performance, to our knowledge, no one has investigated women's willingness to stop HT before a screening mammogram. We were careful to maintain details regarding study nonparticipation. Very little is known about whether a woman would be willing to stop HT for 1 to 2 months if she might have improved breast cancer screening as a result. Although our study did not find improved recall rates among women who stop HT for 1 to 2 months before a mammogram versus women who continued HT use, we did find a decrease in breast density, particularly among women who stop HT use for 2 months. 25 If a larger study were to find improved accuracy of mammogram screening with short-term HT cessation, our study could be an important reminder that many women are unwilling to stop HT regardless of potential benefits.
CONCLUSIONS
Currently, targeting HT discontinuation before a mammogram to a subpopulation of women does not seem feasible because most characteristics between those willing to stop HT for 1 to 2 months and women unwilling to stop HT varied little. However, with additional education for women regarding breast cancer risks, it is unknown whether high-risk groups (ie, women taking EPT who have a first-degree relative with breast cancer) might be more willing to attempt short-term HT cessation before a mammogram.
